Found: 19
Select item for more details and to access through your institution.
A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant.
- Published in:
- Hematology Reports, 2019, v. 11, n. 1, p. 1, doi. 10.4081/hr.2019.7800
- By:
- Publication type:
- Article
Reduced intensity allogeneic stem cell transplant for treatment of blastic plasmacytoid dendritic cell neoplasm.
- Published in:
- 2014
- By:
- Publication type:
- Case Study
Significance of Paraprotein Gap and β2 microglobulins in Predialysis Population with Multiple Myeloma.
- Published in:
- Saudi Journal of Kidney Diseases & Transplantation, 2019, v. 30, n. 4, p. 825, doi. 10.4103/1319-2442.265458
- By:
- Publication type:
- Article
Daratumumab, bortezomib and dexamethasone at first relapse for patients with multiple myeloma: A real‐world multicentre UK retrospective analysis.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 4, p. 682, doi. 10.1111/bjh.18703
- By:
- Publication type:
- Article
The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open‐label, randomised, phase III trial.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 2, p. 267, doi. 10.1111/bjh.18600
- By:
- Publication type:
- Article
A rare presentation of a rare disease: cold haemagglutination disease as the first manifestation of IgM myeloma.
- Published in:
- British Journal of Haematology, 2022, v. 197, n. 6, p. 649, doi. 10.1111/bjh.18117
- By:
- Publication type:
- Article
Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open‐label, randomised, Phase III trial.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 5, p. 853, doi. 10.1111/bjh.16945
- By:
- Publication type:
- Article
COVID‐19 in haematology patients: a multicentre West Midlands clinical outcomes analysis on behalf of the West Midlands Research Consortium.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 1, p. e11, doi. 10.1111/bjh.17136
- By:
- Publication type:
- Article
COVID‐19 in bone marrow transplant recipients: reflecting on a single centre experience.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 2, p. e67, doi. 10.1111/bjh.16856
- By:
- Publication type:
- Article
Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial).
- Published in:
- British Journal of Haematology, 2019, v. 185, n. 3, p. 573, doi. 10.1111/bjh.15551
- By:
- Publication type:
- Article
Autoimmune Cytopenias Developing Late Post Alemtuzumab-Based Allogeneic Stem Cell Transplantation: Presentation of Short Case Series from a Transplant Center.
- Published in:
- 2020
- By:
- Publication type:
- Case Study
Clonal evolution in adult TCF3::HLF-positive acute lymphoblastic leukemia undergoing stem cell transplantation.
- Published in:
- 2022
- By:
- Publication type:
- Letter
Hypokalaemic rhabdomyolysis.
- Published in:
- Annals of Clinical Biochemistry, 2007, v. 44, n. 3, p. 308, doi. 10.1258/000456307780480882
- By:
- Publication type:
- Article
Reduced-intensity conditioning allogeneic transplantation after salvage treatment with DT- PACE in myeloma patients relapsing early after autologous transplant.
- Published in:
- European Journal of Haematology, 2017, v. 99, n. 4, p. 300, doi. 10.1111/ejh.12917
- By:
- Publication type:
- Article
Management of Allogeneic Stem Cell Transplantation for High-Risk AML following SARS-CoV-2 Associated Pancytopenia with Marked Bone Marrow Biopsy Alterations.
- Published in:
- Case Reports in Hematology, 2021, p. 1, doi. 10.1155/2021/8843063
- By:
- Publication type:
- Article
Use Via Early Access to Ixazomib (UVEA-IXA) Study: Effectiveness and Safety of Ixazomib-based Therapy in Relapsed/Refractory Multiple Myeloma Outside of the Clinical Trial Setting.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 2, p. e40, doi. 10.1016/j.clml.2023.10.003
- By:
- Publication type:
- Article
Quadruplet KCRD (Carfilzomib, Cyclophosphamide, Lenalidomide and Dexamethasone) Induction for Newly Diagnosed Myeloma Patients.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e2, doi. 10.1016/j.clml.2019.09.003
- By:
- Publication type:
- Article
Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort.
- Published in:
- PLoS ONE, 2022, v. 17, n. 7, p. 1, doi. 10.1371/journal.pone.0270854
- By:
- Publication type:
- Article